Table 1.
Patient: Gender, Age, Year of Diagnosis |
Clinical Presentation (Duration of Symptoms before Diagnosis) |
PNM Classification (Clinical Stage) |
Diagnosis and Follow Up |
Therapy | Complications |
---|---|---|---|---|---|
No 1: male; 63 y.; 2017 |
Fever, dyspnea, cough, right-sided chest pain (3 y.) |
P4N1M1 (IV) |
MSCT Pathohistology Serology PCR FDG-PET |
Albendazole; Partial resection; Amphotericin B; Mefloquine |
Intraop. bleeding; Pancytopenia, agranulocytosis with sepsis—due to albendazole therapy |
No 2: male; 64 y.; 2019 |
Upper right abdominal quadrant pain; jaundice (5 mo.) |
P4N1M0 (IV) |
MSCT Pathohistology PCR |
Liver lobectomy; Albendazole 2 y. postoperatively | No |
No 3: female; 37 y.; 2021 |
Upper right abdominal quadrant pain (8 mo.) |
P4N0M0 (IIIb) |
MSCT Pathohistology Serology PCR FDG-PET |
Excision; Albendazole postoperatively; Liver transplantation |
Postexcisional: hepatic artery thrombosis; recurrent cholangitis |
No 4: female; 58 y.; 2022 |
Upper right abdominal quadrant pain, nausea (2 mo.) |
P4N0M0 (IIIb) |
MSCT Pathohistology Serology PCR FDG-PET |
Albendazole Partial resection |
No |
No 5: female; 67 y.; 2022 |
Upper right abdominal quadrant discomfort (8 y.) |
P3N0M0 (IIIa) |
MSCT Pathohistology Serology PCR FDG-PET |
Liver lobectomy; Albendazole postoperatively |
Leucopenia; Increased transaminases due to albendazole therapy |
No 6: female; 53 y.; 2022 |
Upper abdominal discomfort, nausea (4 y.) |
P2N0M0 (II) |
MSCT Serology FDG-PET Pathohistology PCR |
Albendazole; Excision |
Increased transaminases and neutropenia due to albendazole therapy |
y.—years; mo.—months; MSCT—Multi-Slice Computed Tomography; PCR—Polymerase Chain Reaction; FDG-PET—Fluorodeoxyglucose-Positron Emission Tomography.